Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Schloemer

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
The New England Journal of Medicine|April 20, 2022
Cardiovascular Events with Finerenone in CKD and Diabetes. ReplyBertram Pitt, Amer Joseph, Patrick Schloemer
Kidney International|September 20, 2025
The authors replyDustin J Little, Samvel B Gasparyan, Patrick Schloemer
Spine|October 3, 2012
Spinal high-velocity low amplitude manipulation in acute nonspecific low back pain: a double-blinded randomized controlled trial in comparison with diclofenac and placeboWolfgang J von Heymann, Patrick Schloemer, Juergen Timm, et al.
Journal of Translational Medicine|March 14, 2026
An integrative framework for drug target discovery bridging clinical trial and genetic data insightsJohanna Mielke, Tobias Strunz, Jeongah Lee, et al.
Kidney International|March 26, 2025
Contribution of the glomerular filtration rate slope to the kidney hierarchical composite endpointDustin J Little, Niels Jongs, Meike Brinker, et al.
Journal of the American Society of Nephrology : JASN|June 17, 2025
Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End PointNiels Jongs, Samvel B Gasparyan, Lars Frison, et al.
American Journal of Nephrology|October 28, 2019
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease TrialGeorge L Bakris, Rajiv Agarwal, Stefan D Anker, et al.
The New England Journal of Medicine|August 27, 2021
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 DiabetesBertram Pitt, Gerasimos Filippatos, Rajiv Agarwal, et al.
Circulation|November 17, 2020
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 DiabetesGerasimos Filippatos, Stefan D Anker, Rajiv Agarwal, et al.
The New England Journal of Medicine|December 2, 2020
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 DiabetesGeorge L Bakris, Rajiv Agarwal, Stefan D Anker, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
The New England Journal of Medicine|April 20, 2022
Cardiovascular Events with Finerenone in CKD and Diabetes. ReplyBertram Pitt, Amer Joseph, Patrick Schloemer
Kidney International|September 20, 2025
The authors replyDustin J Little, Samvel B Gasparyan, Patrick Schloemer
Spine|October 3, 2012
Spinal high-velocity low amplitude manipulation in acute nonspecific low back pain: a double-blinded randomized controlled trial in comparison with diclofenac and placeboWolfgang J von Heymann, Patrick Schloemer, Juergen Timm, et al.
Journal of Translational Medicine|March 14, 2026
An integrative framework for drug target discovery bridging clinical trial and genetic data insightsJohanna Mielke, Tobias Strunz, Jeongah Lee, et al.
Kidney International|March 26, 2025
Contribution of the glomerular filtration rate slope to the kidney hierarchical composite endpointDustin J Little, Niels Jongs, Meike Brinker, et al.
Journal of the American Society of Nephrology : JASN|June 17, 2025
Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End PointNiels Jongs, Samvel B Gasparyan, Lars Frison, et al.
American Journal of Nephrology|October 28, 2019
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease TrialGeorge L Bakris, Rajiv Agarwal, Stefan D Anker, et al.
The New England Journal of Medicine|August 27, 2021
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 DiabetesBertram Pitt, Gerasimos Filippatos, Rajiv Agarwal, et al.
Circulation|November 17, 2020
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 DiabetesGerasimos Filippatos, Stefan D Anker, Rajiv Agarwal, et al.
The New England Journal of Medicine|December 2, 2020
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 DiabetesGeorge L Bakris, Rajiv Agarwal, Stefan D Anker, et al.
Pageof 5